`Filed: May 13, 2020
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`ACRUX DDS PTY LTD., ACRUX LIMITED, and
`ARGENTUM PHARMACEUTICALS LLC,
`Petitioners,
`
`v.
`
`KAKEN PHARMACEUTICAL CO., LTD. and
`VALEANT PHARMACEUTICALS INTERNATIONAL, INC.,
`Patent Owners.
`
`
`
`
`
`
`
`
`Case IPR2017-001901
`U.S. Patent No. 7,214,506
`
`
`
`
`
`
`
`
`JOINT MOTION TO TERMINATE PROCEEDING AND REQUEST TO
`TREAT SETTLEMENT AGREEMENT AS BUSINESS CONFIDENTIAL
`INFORMATION AND BE KEPT SEPARATE
`PURSUANT TO 35 U.S.C. § 317 AND 37 C.F.R. § 42.72 & 42.74
`
`
`
`
`
`1 Case IPR2017-01429 has been joined with the instant proceeding.
`
`
`
`
`
`Pursuant to 35 U.S.C. § 317 and 37 C.F.R. §§ 42.74 & 42.74, Patent Owners
`
`Case IPR2017-00190
`Patent No. 7,214,506
`
`
`
`
`Kaken Pharmaceutical Co., Ltd. and Bausch Health Companies Inc. (formerly
`
`known as Valeant Pharmaceuticals International, Inc.) (“Patent Owners”) and
`
`Petitioners Acrux DDS PTY Ltd. and Acrux Ltd. (“Acrux”) respectfully jointly
`
`request termination of the inter partes review of U.S. Patent No. 7,214,506 (“the
`
`’506 Patent”), Case No. IPR2017-00190, which is on remand from the United States
`
`Court of Appeals for the Federal Circuit, and further jointly request that the
`
`Settlement Agreement between the parties, filed concurrently herewith, be treated
`
`as business confidential information, be kept separate from the file of the involved
`
`’506 Patent, and be made available only as permitted pursuant to the provisions of
`
`35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c).
`
`I.
`
`No Petitioners Remain in this Remanded IPR
`
`This IPR is pending before the Board after the Federal Circuit vacated,
`
`reversed, and remanded the initial Final Written Decision. Kaken Pharm. Co., Ltd.
`
`v. Bausch Health Co. Inc., 952 F.3d 1346 (Fed. Cir. 2020). After the Board issued
`
`the Final Written Decision on June 6, 2018 finding the claims of the ’506 Patent
`
`invalid (Paper No. 80), Patent Owners filed a Notice of Appeal to the Federal Circuit.
`
`(Paper No. 86). Petitioner Argentum did not enter an appearance at the Federal
`
`Circuit and no longer remains in this resultant remanded proceeding. Kaken Pharm.
`
`Co., Ltd. v. Bausch Health Co. Inc., No. 18-2232, D.E. 23 (Fed. Cir. Oct. 23, 2018)
`
`1
`
`
`
`
`(“Official caption revised to reflect lack of appearance on behalf of Argentum
`
`Case IPR2017-00190
`Patent No. 7,214,506
`
`Pharmaceuticals LLC.”). After Patent Owners filed their initial brief at the Federal
`
`Circuit, but before appellee’s brief was due, Petitioner Acrux and Patent Owners
`
`settled their dispute involving the ’506 Patent. See Confidential Exhibit 2204. Days
`
`later, congruent with the settlement agreement, Petitioner Acrux submitted a Notice
`
`of Non-Participation in the appeal. Kaken Pharm. Co., Ltd. v. Bausch Health Co.
`
`Inc., No. 18-2232, D.E. 35 (Fed. Cir. April 4, 2019) (“Appellees Acrux DDS Pty
`
`Ltd. and Acrux Limited hereby give notice that they will not participate in this appeal
`
`and will not file an Appellees’ brief.”); D.E. 36 (revising caption to remove Acrux
`
`DDS Pty Ltd. and Acrux Limited).2 After the Federal Circuit issued the Order
`
`reflecting Petitioner Acrux’s withdrawal, the U.S. Patent and Trademark Office
`
`(“the PTO”) intervened in the appeal.
`
`On March 13, 2020, the Federal Circuit vacated the Board’s Final Written
`
`Decision and remanded the case back to the Board. Kaken, 952 F.3d 1346. The
`
`PTO did not petition for rehearing at the Federal Circuit and the deadline for such
`
`
`2 A Stipulated Dismissal and Injunction was entered against Petitioner Acrux DDS
`Pty Ltd. in a district court action involving the ’506 Patent. Valeant Pharms. N.A.
`LLC v. Acrux DDS Pty Ltd., Case No. 18-cv-14194, D.E. 27 (D.N.J. April 10, 2019).
`Petitioner Argentum was not involved at the district court. The ’506 Patent is also
`being asserted in district court actions that do not involve any Petitioners. In re
`Jublia, Case No. 18-cv-13635 (D.N.J.); Valeant Pharms. N.A. LLC v. Mylan Pharms
`Inc., Case No. 18-cv-184 (N.D.W.Va.)
`
`2
`
`
`
`
`petition expired on April 27, 2020. The Federal Circuit mandate issued May 4, 2020.
`
`Case IPR2017-00190
`Patent No. 7,214,506
`
`The Board has not yet issued a Final Written Decision in the remanded case. On
`
`May 11, 2020, the Board authorized Patent Owners and Petitioner Acrux to file
`
`(1) this joint motion to terminate and (2) a joint request that the settlement agreement
`
`be treated as business confidential information under 37 C.F.R. § 42.74(c).
`
`II. Termination Is Appropriate
`
`Under 35 U.S.C. § 317(a), “[i]f no petitioner remains in the inter partes
`
`review, the Office may terminate the review or proceed to a final written decision
`
`under section 318(a).” See also 37 C.F.R. § 42.74 (“[t]he parties may agree to settle
`
`any issue in a proceeding . . .”); § 42.72 (“The Board may terminate a trial without
`
`rendering a final written decision, where appropriate, including where the trial is
`
`consolidated with another proceeding or pursuant to a joint request under 35 U.S.C.
`
`317(a) or 327(a).”).
`
`Termination of the proceeding is appropriate because no dispute remains
`
`between the Parties and the Board has not issued a final written decision in this
`
`remanded proceeding. Patent Owners and Petitioner Acrux have settled their dispute
`
`involving the ’506 Patent (see Confidential Exhibit 2204). Petitioner Argentum
`
`3
`
`
`
`
`withdrew from the proceeding while the case was before the Federal Circuit.3 Patent
`
`Case IPR2017-00190
`Patent No. 7,214,506
`
`Owners and Petitioner Acrux jointly support termination of these proceedings.
`
`III. Treat Settlement Agreement as Business Confidential Information
`
`Pursuant to 37 C.F.R. § 42.74(b), a true and unredacted copy of the written
`
`settlement agreement between Patent Owners and Petitioner Acrux is filed herewith
`
`as Confidential Exhibit 2204. There are no other agreements or understandings
`
`between the Parties made in connection with, or in contemplation of, the termination
`
`of this proceeding. Patent Owners and Petitioner Acrux hereby jointly request that
`
`the settlement agreement be treated as business confidential information, be kept
`
`separate from the file of the involved ’506 Patent, and be made available only to
`
`Federal Government agencies on written request, or to any person on a showing of
`
`good cause pursuant to 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c).
`
`
`3 Counsel for Petitioner Argentum was contacted regarding this motion on April 22,
`2020. To date, Petitioner Argentum has not provided a position regarding this
`motion or a timeframe in which it will.
`
`4
`
`
`
`
`
`
`
`Dated: May 13, 2020
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case IPR2017-00190
`Patent No. 7,214,506
`
`Respectfully submitted,
`
`By: /John D. Livingstone/
`John D. Livingstone
`Finnegan, Henderson, Farabow,
` Garrett & Dunner, LLP
`Reg. No. 59,613
`
`Lead Counsel for Patent Owner
`
`By: /Tara M. Raghavan/
`Tara M. Raghavan
`Rakoczy Molino Mazzochi
`Siwik LLP
`6 W. Hubbard Street, Suite 500
`Chicago, IL 60654
`Telephone: 312-222-6340
`E-mail:
`traghavan@rmmslegal.com
`Reg. No. 55,557
`
`Lead Counsel for Petitioners
`Acrux DDS PTY Ltd. and
`Acrux Limited
`
`5
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`Case IPR2017-00190
`Patent No. 7,214,506
`
`The undersigned certifies that a copy of the foregoing Joint Motion To
`
`Terminate Proceeding And Request To Treat Settlement Agreement As
`
`Business Confidential Information And Be Kept Separate Pursuant To 35
`
`U.S.C. § 317 And 37 C.F.R. § 42.72 & 42.74 was served electronically via email
`
`on May 13, 2020, in its entirety on the following:
`
`Tara M. Raghavan
`Steven J. Birkos
`William A. Rakoczy
`Joseph T. Jaros
`Rakoczy Molino Mazzochi Siwik LLP
`6 West Hubbard Street, Suite 500
`Chicago, Illinois 60654
`traghavan@rmmslegal.com
`sbirkos@rmmslegal.com
`wrakoczy@rmmslegal.com
`jjaros@rmmslegal.com
`
`Teresa Stanek Rea
`Shannon M. Lentz
`Crowell & Moring LLP
`Intellectual Property Group
`1001 Pennsylvania Ave., NW
`Washington, DC 20004-2595
`trea@crowell.com
`slentz@crowell.com
`
`Tyler C. Liu
`Argentum Pharmaceuticals, LLC
`tliu@agpharm.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case IPR2017-00190
`Patent No. 7,214,506
`
`By: / John D. Livingstone /
`John D. Livingstone
`Reg. No. 59,613
`
`
`
`
`
`